You are here

Circulating Diagnostic Markers of Infectious Disease

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-P-0315
Agency Tracking Number: C18A-001-0002
Amount: $149,503.95
Phase: Phase I
Program: STTR
Solicitation Topic Code: CBD18A-001
Solicitation Number: 2018.0
Solicitation Year: 2018
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-20
Award End Date (Contract End Date): 2019-03-20
Small Business Information
1024 Roy J. Carver Co-Laboratory
Ames, IA 50011
United States
DUNS: 832427822
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Manohar John
 (781) 244-4505
Business Contact
 Manohar John
Phone: (781) 244-4505
Research Institution
 Iowa State University of Science and Technology
 Manohar John
Office of Sponsored Programs Administration
Ames, IA 50011-2103
United States

 (781) 244-4505
 Nonprofit College or University

The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-derived proteins shed incirculation (shed proteins) during the process of infection. PELS is a proprietary, fully validated, highly sensitive platform proteome miningtool for discovery of the gamut of protein antigens expressed by any microbe during infection. Specifically, proof-of-concept will bedemonstrated by identifying a panel of proteins unique to virulent Brucella melitensis strain16 M that are shed in murine sera, collected atvarious time points following experiment infection of mice with the cognate pathogen. Phase II studies will involve application of this Phase Ivalidatedplatform technical approach to defining shed proteins in sera of patients infected with Brucella species and Rickettsia prowazekii,and in sera and cerebrospinal fluid of individuals infected with the Venezuelan Equine Encephalitis virus, followed by marker validation anddevelopment of prototype diagnostic assays. Phase III will involve partnered in vitro diagnostic instrument development and validationstudies for FDA approval, and commercialization.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government